Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan

被引:1
作者
Hida, Tokimasa [1 ]
Idogawa, Masashi [2 ]
Kato, Junji [1 ]
Kiniwa, Yukiko [3 ]
Horimoto, Kohei [1 ]
Sato, Sayuri [1 ]
Sawada, Masahide [1 ]
Tange, Shoichiro [2 ]
Okura, Masae [1 ]
Okuyama, Ryuhei [3 ]
Tokino, Takashi [2 ]
Uhara, Hisashi [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Japan
[2] Sapporo Med Univ, Canc Res Inst, Sch Med, Dept Med Genome Sci, Sapporo, Japan
[3] Shinshu Univ, Sch Med, Dept Dermatol, Nagano, Japan
来源
CANCER MEDICINE | 2024年 / 13卷 / 22期
基金
日本学术振兴会;
关键词
DNA copy number variation; immune checkpoint inhibitor; melanoma; molecular targeted therapy; mutation; BRAF; DACARBAZINE; IPILIMUMAB; INHIBITORS; SURVIVAL; CANCER; NRAS;
D O I
10.1002/cam4.70360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAcral and mucosal melanomas are more prevalent in Asians than in Caucasians, unlike cutaneous melanomas, which are predominant in Caucasians. Recent studies have suggested that non-Caucasian cutaneous melanomas responded less to immune checkpoint inhibitors, highlighting the need for genetic profiling across ethnicities. This study aimed to elucidate the genetic characteristics of Japanese melanomas, which is an under-researched topic.MethodsSingle-nucleotide variants, indels, and copy number alterations in 104 Japanese melanoma patients (37 cutaneous, 52 acral, and 15 mucosal) were analyzed using custom panel sequencing.ResultsDriver events were detected in 94% of the cases. Among cutaneous melanoma cases, 76% had BRAF mutations, and 8% had NRAS mutations. In acral melanoma, BRAF (9%), NRAS (17%), KRAS (8%), KIT (19%), and NF1 (7%) mutations were detected. Major driver mutations in mucosal melanoma were detected in NRAS, KRAS, NF1, PTEN, GNAQ, and KIT. The median tumor mutational burden across all melanoma types was 4.6 mutations/Mb, with no significant difference between the cutaneous and acral/mucosal types. Of the 21 patients with both primary and metastatic lesions, 11 showed distinct mutations in each. Potentially actionable mutations were detected in 58 patients in addition to BRAF V600E/K mutations in 31.ConclusionsThis study highlights distinct genetic abnormalities and actionable alterations in Japanese melanoma patients. This suggests a lower tumor mutational burden in East Asian cutaneous melanoma, which may affect the efficacy of immune checkpoint inhibitors. The heterogeneity of driver mutations across and within individuals highlights the need for personalized treatment approaches.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Genomic Classification of Cutaneous Melanoma
    Akbani, Rehan
    Akdemir, Kadir C.
    Aksoy, B. Arman
    Albert, Monique
    Ally, Adrian
    Amin, Samirkumar B.
    Arachchi, Harindra
    Arora, Arshi
    Auman, J. Todd
    Ayala, Brenda
    Baboud, Julien
    Balasundaram, Miruna
    Balu, Saianand
    Barnabas, Nandita
    Bartlett, John
    Bartlett, Pam
    Bastian, Boris C.
    Baylin, Stephen B.
    Behera, Madhusmita
    Belyaev, Dmitry
    Benz, Christopher
    Bernard, Brady
    Beroukhim, Rameen
    Bir, Natalie
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Boland, Genevieve M.
    Bono, Riccardo
    Bootwalla, Moiz S.
    Bosenberg, Marcus
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brockway-Lunardi, Laura
    Brooks, Denise
    Brzezinski, Jakub
    Bshara, Wiam
    Buda, Elizabeth
    Burns, William R.
    Butterfield, Yaron S. N.
    Button, Michael
    Calderone, Tiffany
    Cappellini, Giancarlo Antonini
    Carter, Candace
    Carter, Scott L.
    Cherney, Lynn
    Cherniack, Andrew D.
    Chevalier, Aaron
    Chin, Lynda
    [J]. CELL, 2015, 161 (07) : 1681 - 1696
  • [2] The Implications of Clonal Genome Evolution for Cancer Medicine
    Aparicio, Samuel
    Caldas, Carlos
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (09) : 842 - 851
  • [3] Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
    Bai, Xue
    Shoushtari, Alexander N.
    Warner, Allison Betof
    Si, Lu
    Tang, Bixia
    Cui, Chuanliang
    Yang, Xiaoling
    Wei, Xiaoting
    Quach, Henry T.
    Cann, Christopher G.
    Zhang, Michael Z.
    Pallan, Lalit
    Harvey, Catriona
    Kim, Michelle S.
    Kasumova, Gyulnara
    Sharova, Tatyana
    Cohen, Justine, V
    Lawrence, Donald P.
    Freedman, Christine
    Fadden, Riley M.
    Rubin, Krista M.
    Frederick, Dennie T.
    Flaherty, Keith T.
    Long, Georgina, V
    Menzies, Alexander M.
    Sullivan, Ryan J.
    Boland, Genevieve M.
    Johnson, Douglas B.
    Guo, Jun
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : 401 - 410
  • [4] Bastian B. C., 2023, WHO Classification of Tumours Editorial Board. Skin Tumours Internet
  • [5] Beta Version Ahead of Print. Lyon (France): International Agency for Research on Cancer, V12
  • [6] Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data
    Boeva, Valentina
    Popova, Tatiana
    Lienard, Maxime
    Toffoli, Sebastien
    Kamal, Maud
    Le Tourneau, Christophe
    Gentien, David
    Servant, Nicolas
    Gestraud, Pierre
    Frio, Thomas Rio
    Hupe, Philippe
    Barillot, Emmanuel
    Laes, Jean-Francois
    [J]. BIOINFORMATICS, 2014, 30 (24) : 3443 - 3450
  • [7] Systematic review and meta-analysis of genomic alterations in acral melanoma
    Broit, Natasa
    Johansson, Peter A.
    Rodgers, Chloe B.
    Walpole, Sebastian T.
    Hayward, Nicholas K.
    Pritchard, Antonia L.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2022, 35 (03) : 369 - 386
  • [8] Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011
  • [9] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
    Chapman, Paul B.
    Hauschild, Axel
    Robert, Caroline
    Haanen, John B.
    Ascierto, Paolo
    Larkin, James
    Dummer, Reinhard
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Hogg, David
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    Ribas, Antoni
    O'Day, Steven J.
    Sosman, Jeffrey A.
    Kirkwood, John M.
    Eggermont, Alexander M. M.
    Dreno, Brigitte
    Nolop, Keith
    Li, Jiang
    Nelson, Betty
    Hou, Jeannie
    Lee, Richard J.
    Flaherty, Keith T.
    McArthur, Grant A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516
  • [10] COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
    Dummer, Reinhard
    Flaherty, Keith T.
    Robert, Caroline
    Arance, Ana
    de Groot, Jan Willem B.
    Garbe, Claus
    Gogas, Helen J.
    Gutzmer, Ralf
    Krajsova, Ivana
    Liszkay, Gabriella
    Loquai, Carmen
    Mandala, Mario
    Schadendorf, Dirk
    Yamazaki, Naoya
    di Pietro, Alessandra
    Cantey-Kiser, Jean
    Edwards, Michelle
    Ascierto, Paolo A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4178 - +